Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Jnj save search
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
avb-101 first dementia for trial
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.84%
H: 0.0%
C: 0.0%
neuroinflammatory back trials
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and Clinical Trial Activity Reflect Growing Interest in the Market
Published: 2024-03-15 (Crawled : 15:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
partnership precision global trends growing trial market
Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
conference year international trials therapeutics
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
Published: 2024-03-01 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
hospital pharmaceuticals global medical trial
Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review 2024
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.99%
H: 2.47%
C: 2.08%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
review trials global
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024: PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
Published: 2024-02-28 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.56%
H: 0.12%
C: -0.38%
trials global therapy market
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for ...
Published: 2024-02-22 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for Inclusivity
Published: 2024-02-22 (Crawled : 09:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: -0.23%
H: 0.54%
C: -1.13%
jnj-2113 psoriasis study
J&J Touts Positive Phase III Results for Antibody in Autoimmune Disorders
Published: 2024-02-06 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
antibody positive disorders results
TREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study
Published: 2024-01-22 (Crawled : 14:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
tremfya rapid psoriasis clearance study
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
Published: 2023-12-15 (Crawled : 12:30) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -4.44%
H: 0.0%
C: 0.0%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: -1.62%
H: 9.04%
C: 7.4%
disease active alzheimer’s immunotherapy trial
J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myel...
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
darzalex eye faspro
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-12-13 (Crawled : 13:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: 0.1%
H: 3.85%
C: 3.72%
jnj-2113 active payment milestone study
BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn
Published: 2023-12-12 (Crawled : 21:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
disease global collaboration trial
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.64%
H: 0.02%
C: -0.66%
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: -0.58%
H: 2.19%
C: 1.69%
jnj-2113 psoriasis
MustGrow Receives PMRA Approval to Commence Large Scale Field Trials via NexusBioAg BAT Program
Published: 2023-11-07 (Crawled : 18:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
approval trials program
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 11.35%
H: 9.32%
C: -4.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
cyb003 rapid positive depression meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.